Prelude Capital Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,700
| Closed | -$11K | – | 932 |
|
|
2020
Q3 | $11K | Buy |
1,700
+1,300
| +325% | +$8.41K | ﹤0.01% | 1083 |
|
|
2020
Q2 | $3K | Buy |
+400
| New | +$3K | ﹤0.01% | 1201 |
|
|
2019
Q3 | – | Sell |
-611
| Closed | -$7K | – | 1259 |
|
|
2019
Q2 | $7K | Buy |
+611
| New | +$7K | ﹤0.01% | 1065 |
|
|
2018
Q4 | – | Sell |
-72
| Closed | -$1K | – | 1446 |
|
|
2018
Q3 | $1K | Sell |
72
-10,385
| -99% | -$144K | ﹤0.01% | 1315 |
|
|
2018
Q2 | $239K | Buy |
10,457
+9,254
| +769% | +$212K | 0.02% | 559 |
|
|
2018
Q1 | $34K | Buy |
1,203
+802
| +200% | +$22.7K | ﹤0.01% | 1036 |
|
|
2017
Q4 | $8K | Buy |
+401
| New | +$8K | ﹤0.01% | 1091 |
|
|
2017
Q3 | – | Sell |
-300
| Closed | -$5K | – | 1531 |
|
|
2017
Q2 | $5K | Buy |
+300
| New | +$5K | ﹤0.01% | 1341 |
|